The North America percutaneous mechanical circulatory support devices market is expected to reach US$ 1,749.25 million by 2027 from US$ 645.23 million in 2019; it is estimated to grow at a CAGR of 13.6% from 2020 to 2027.
The increasing geriatric population, increasing prevalence of cardiovascular diseases and shortage of heart donors are the key factors driving the growth of percutaneous mechanical circulatory support devices. However, high costs of these devices and procedures associated with them as well as product recalls, and impact of COVID-19 pandemic on medical device industry is the major factor hindering the Percutaneous Mechanical Circulatory Support Devices market growth in North America.Percutaneous mechanical circulatory support devices offers an effective and rapid approach to slow the downward spiral of hemodynamic instability among patients suffering with decompensated heart failures and cardiogenic shocks till a more definitive strategy is perceived among patients to recover from these cardiac ailments. The major roles of the percutaneous mechanical circulatory support devices include improving the native cardiac output, reducing ventricular volume and filling pressures, augmenting coronary perfusion, and maintaining vital organ perfusion.
Heart transplantation has been accepted as the best treatment for patients with medically refractory end-stage heart failure. A central fact about organ transplantation, and heart transplantation, in particular, is the scarcity of organs for transplant. Annual figures published by NHS Blood and Transplant in 2015, showed that there is still a vast shortage of organ donors. There are currently 286 patients on the waiting list for a heart transplant, compared with 126 in 2010. The number of people desperately waiting for a heart transplant has more than doubled in just five years, according to the latest statistics. According to a report published by Ottawa Heart Institute in April 2018, more than 5,000 Canadians could benefit from a heart transplant. However, only 170 transplants were performed annually in Canada due to chronic heart donor shortage.
Patients with advanced heart failure have a poor prognosis, and a heart transplant is still the best treatment option. However, the scarcity of donors, long waiting times, and an increasing number of unstable patients have favored the development of mechanical circulatory support.
Moreover, according to the Heart Failure Society of America, nearly 5.7 million Americans are suffering from heart failure. The data also suggests that almost 1.4 million persons with CHF are under 60 years of age. The Centers for Disease Control and Prevention (CDC) reports that about half of people who develop heart failure die within five years of diagnosis. The cost of heart failure in the US is estimated to be US$ 30.7 billion each year. According to the Mount Sinai Heart Center, every day in America, 33 people die in need of new organs, and about 115,000 people are languishing on waiting lists.
The chronic shortage of heart donors has also led to extend the age limits of donors in certain areas. Thus, the solution to this shortage of heart donors served by the temporarily used percutaneous mechanical circulatory support devices that are also helpful in long-term support for patients suffering from heart failures is likely to be adopted at higher rates in the coming years.
North America is witnessing the growing number of COVID-19 cases. Due to coronavirus spreading, many cities are shutting down, causing treatments and doctors/cardiologists appointment cancellation. Companies operating in the percutaneous mechanical circulatory support devices have limited their production of percutaneous mechanical circulatory support devices. As the treatment procedures are directly contacted with patients’ oral fluid that has a possible risk of infections, for the preventing the spread of COVID-19 it is requested to maintain social distancing as there is a greater risk of getting infected with coronavirus due to direct exposure to oral fluids of the patients. Thus, owing to these factors, the increased production for diagnostics test kits and ventilators are likely to hinder the growth of the percutaneous mechanical circulatory support devices market
Mexico Percutaneous Mechanical Circulatory Support Devices Market, Revenue and Forecast to 2027 (US$ Mn)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
NORTH AMERICA PERCUTANEOUS MECHANICAL CIRCULATORY SUPPORT DEVICES MARKET SEGMENTATION
By Product
- Intra-Aortic Balloon Pumps
- VA-Extracorporeal Membrane Oxygenation (ECMO)
- Short-Term Ventricular Assist Devices (VADs)
- Impella
- Tandem Heart
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
By Country
- US
- Canada
- Mexico
Company Profiles
- Abbott
- Teleflex Incorporated
- Abiomed
- Jarvik Heart, Inc
- Medtronic
North America Percutaneous Mechanical Circulatory Support Devices Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 645.23 Million |
Market Size by 2027 | US$ 1,749.25 Million |
Global CAGR (2020 - 2027) | 13.6% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















- Abbott
- Teleflex Incorporated
- Abiomed
- Jarvik Heart, Inc
- Medtronic


